Ono and Galapagos Sign an Additional Target Discovery Agreement
News May 30, 2012
Galapagos NV and Ono Pharmaceutical Co., Ltd. have announced that they have signed an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma.
In the new agreement, Galapagos’ service division BioFocus will use its SilenceSelect® platform to deliver validated targets to Ono.
Ono aims to find modulators for these targets and generate novel drug candidates. Financial details were undisclosed.
“We are delighted with the success of our relationship with Ono,” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus.
Dr Newton continued, “The start of a new collaboration one year after the first one is testament to our target discovery platform and the strength of our partnership.”
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “This new project builds upon a novel human primary cell-based assay developed by BioFocus in the field of allergic diseases, an area with significant unmet medical needs. We are excited to apply BioFocus’ target discovery platform to discover and validate novel drug targets.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.